Solution
Industries
Resources
About

Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets

Report Code: PHM069A

Publish Date: Sep 2010

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

  • The total worldwide market for MS disease-modifying therapies is expected to grow at an 8.1% compound annual growth rate (CAGR) from 2010 through 2015, with sales reaching nearly $16.7 billion by the end of 2015, from $11.3 billion in 2010.
  • From 2010 through 2015, the overall small molecule MS disease-modifying drug market is expected to grow rapidly. This segment is worth an estimated $3.6 billion in 2010 and is projected to increase at a 17.4% compound annual growth rate (CAGR) to reach $7.9 billion in 2015.
  • Biologics represent the largest class of MS disease-modifying therapies by sales and by number of approved therapies. This sector is valued at $7.8 billion in 2010 and is expected to increase at a 2.5% compound annual growth rate (CAGR) to reach a value of $8.8 billion in 2015.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
 
BCC’s goal in conducting this study was to determine the current status of the market for disease-modifying multiple sclerosis (MS) drugs, biologics, and vaccines and to assess their growth potential over a 5-year period from 2010 through 2015.
 
MS is an autoimmune disease characterized by the body’s own immune system attacking itself and causing spots of demyelination (plaques) in the brain and spinal cord. Symptoms of MS vary widely depending on the severity of the disease and which nerve cells are attacked. Today there are currently eight disease-modifying therapies for MS approved throughout the world. Biologics represent the largest class of MS disease-modifying therapies by sales and by number of approved therapies accounting for six out of the eight approved MS disease-modifying products (Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri). Of these biologics, five are beta interferon products. All of these approved MS agents are able to slow down the progression of the disease but none can reverse any nerve damage that occurs due to demyelination.
 
The initial 2004 Food and Drug Administration (FDA) approval of Biogen Idec’s and Elan’s Tysabri marked the approval of the first therapeutic for MS that may actually reverse some of the effects of MS. Other novel compounds in late-stage clinical testing, such as Novartis’ Gilenia (fingolimod, FTY720), Merck KGaA’s Mylinax (oral cladribine), and Genzyme’s Campath (alemtuzumab) have unique routes of administration and mechanisms of action that may also have a large effect on how MS is treated in the future. Finally, biosimilar versions of existing biologics and new molecular entities in late-stage clinical testing may also play a major role in shaping the market for MS products through 2015. 
 
For each drug or biologic for MS on the market, all agents for MS in mid-to-late stages of clinical development, and some in earlier stages of development we have examined where these compounds stand in the development process, the major challenges to their regulatory approval or market success, their competitive profile, and, if applicable, their projected sales through 2015.
 
We were particularly interested in profiling small molecule drugs, therapeutic vaccines and other biologics targeting MS that are in Phase II or III clinical studies or those with unique mechanisms of action in earlier stages of development.   We identify the leading MS treatments by formulation, by mechanism of action, and by geographic location. In some cases, we discuss notable compounds that failed in clinical testing, such as Roche and Biogen Idec’s Rituxan (rituximab), or that were pulled from the market due to adverse event or other issues. We also discuss the potential of some compounds that are being tested for other inflammatory or autoimmune disorders that could in the future potentially be tested as a treatment for or used off-label for MS.
 
Our main objective is to present a comprehensive analysis of the current market for MS disease-modifying products and to forecast this market’s future direction through 2015.
 
REASONS FOR DOING THIS STUDY
 
Disease-modifying agents to treat MS are currently one of the largest classes of pharmaceutical products by sales in the U.S. and throughout the world. Sales of these agents for MS have grown from less than $1 billion worldwide in 1999 to more than $10 billion in 2009. A period of dynamic growth in the MS disease-modifying product market is expected to continue with seven new agents with unique mechanisms of action or new formulations entering the market between 2010 and the end of 2015. Longer-acting formulations of existing MS products are also expected to have a positive effect on the market as well.
 
New approaches to treating MS are being pursued by pharmaceutical and biotech companies as many of them look to move beyond agents such as the interferons that primarily slow the progression of MS. These potential new disease-modifying agents with novel mechanisms of action or improved delivery systems will provide powerful new options for patients failing or intolerable to the currently prescribed treatments for MS. 
 
INTENDED AUDIENCE
 
We have compiled detailed profiles of the MS disease-modifying products on the market in the U.S. and around the world. We discuss all disease-modifying products in the Phase I, II, and III stages of clinical development and some unique treatments in the preclinical stage of development as well. This study includes technical descriptions of these products, discussion of their individual efficacy and side effect profiles when possible, what stage of the disease they treat, the major companies focusing on their development, and international aspects affecting these products. We provide sales forecasts and the reasoning behind our forecasts for products that are on the market already or that may enter the market through 2015.
 
This study will be of interest to members of the pharmaceutical, healthcare, and biotechnology industries. It will also be a valuable resource for investors that invest in the pharmaceutical sector. It is written in such a way as to be accessible to an investor or businessperson while maintaining a high level of technical detail.
 
SCOPE OF REPORT
 
At the beginning of 2010, there were eight disease-modifying agents for MS actively being sold on the worldwide market. The emphasis of this report is on these products and the more than 33 products for MS in various stages of clinical development. 
 
Special focus is placed on how new products and technologies will affect current market leaders in the MS treatment sector. Profiles are provided of companies projected to have disease-modifying products on the market during the forecast period and on companies with rich or interesting pipelines.
 
Included in this report are forecasts for sales by product, company, geographic region, formulation, and indication (if possible) from 2010 through 2015, including supporting analyses for projections.
 
Market trends are assessed based on projected sales of new products being introduced, competitive advantages of emerging products as well as other factors such as increases in the diagnosis of MS in parts of the world.
 
The study is arranged to offer an overview of the MS disease-modifying product market, including regulatory issues, and accompanied by detailed analyses and forecasts by product. Profiles of the many emerging competitors in this sector provide a comprehensive assessment of the various products and technologies entering this market as well as marketing strategies being used to gain a competitive edge.
 
METHODOLOGY
 
The market assessments in this report have been assembled based on publicly available information through 2010-07-15. The base year for the report for forecasting purposes is 2010 and forecast data is provided through 2015. Market figures are based on current dollars, and inflation (outside of its effects on drug pricing) is not computed into the projected forecast figures. Interviews with industry professionals were also used to adjust market size estimates as well as to formulate market projections.
 
MS disease-modifying product development is still evolving as new immunomodulatory treatments are discovered, and other targets prove to be futile in development. The reader is cautioned to use the report data primarily as a guide to assess trends, developments, and challenges that the industry faces.
 
INFORMATION SOURCES
 
The information contained in this report has been assembled from both primary and secondary data sources. Primary research was conducted via in-person, telephone, and email correspondences with selected industry professionals, company executives, research scientists, and laboratory heads to discover the most recent developments in the MS disease-modifying space. Secondary data was collected via a comprehensive search of scientific peer-reviewed literature, presentations at medical conferences clinical trial reports, databases such as PubMed, industry trade media, company websites, annual reports, and industry press releases.
 
AUTHOR’S CREDENTIALS
 
Brian Lawler has more than 4 years of experience working as an analyst covering the pharmaceutical and biotechnology industries. Trained at the University of Southern California, he holds a B.A. degree in economics. 
 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers 
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use. 
Need pricing for multiple titles, a complete report bundle, or something specially curated to fit your budget? EXPLORE OFFERS
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
[+] Show Chapter Details
Title/Chapter NamePagesMember Price
Full Report: Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets162Free
Chapter- 1: INTRODUCTION5Free
Chapter- 2: SUMMARY3Free
Chapter- 3: OVERVIEW22Free
Chapter- 4: TECHNOLOGY 3Free
Chapter- 5: PATENT EVALUATION4Free
Chapter- 6: SMALL MOLECULE MS DRUGS 33Free
Chapter- 7: BIOLOGICS FOR MS43Free
Chapter- 8: DISEASE APPLICATIONS7Free
Chapter- 9: MAJOR COMPANIES AND MARKET SHARE26Free
Chapter- 10: INTERNATIONAL ASPECTS AND REGULATORY ISSUES12Free
Chapter- 11: FUTURE DIRECTIONS4Free

Related Reports

Track the Latest Global Tariff Developments

In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.

Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.

Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.

With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.

Ready to see what tariff means for your business?

Consult with our experts or request your custom Tariff Impact Brife today

Stay Informed, Stay Competitive

In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.

Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.

Our analysis includes:

  • Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
  • Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
  • Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.

With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.

Don't let tariffs catch you off guard—let our insights guide your strategy.

This is an Excel-only version of the report.

Report Includes

    Total Number of Tables in this Report: 47

  • Summary Table: GLOBAL MARKET FOR MS DISEASE-MODIFYING PRODUCTS, THROUGH 2015
  • Table 1: MS STATISTICS FROM AROUND THE WORLD, 2008
  • Table 2: CURRENTLY APPROVED MS THERAPIES ON THE MARKET
  • Table 3: FEATURES OF SMALL MOLECULE VERSUS BIOLOGIC MS DISEASE-MODIFYING THERAPIES
  • Table 4: WHOLESALE ACQUISITION COST OF SELECTED THERAPIES FOR MS, 2009
  • Table 5: COMPARISON OF SIDE EFFECT PROFILES OF MARKETED AND LATE-CLINICAL STAGE THERAPIES FOR MS
  • Table 6: MS THERAPIES IN CLINICAL TRIALS, ORDERED BY PHASE
  • Table 7: MS THERAPIES IN DEVELOPMENT, BY PHASE
  • Table 8: COMPANIES WITH MORE THAN ONE MS THERAPY IN ACTIVE CLINICAL TRIALS OR ON THE MARKET*
  • Table 9: EFFICACY RESULTS OF MS DISEASE-MODIFYING THERAPIES
  • Table 10: GLOBAL MARKET FOR MS DISEASE-MODIFYING THERAPIES BY CLASS, THROUGH 2015
Sample Report

Recent Reports

Clinical Nutrition: Global Markets to 2031

Published - Jun 2026 | Publisher - BCC Publishing | Code - PHM198C

The global market for clinical nutrition is expected to grow from $79.5 billion in 2026 and is projected to reach $104.7 billion by the end of 2031, at a compound annual growth rate (CAGR) of 5.6% during the forecast period of 2026 to 2031.

Substance Use Disorder Treatment: Global Markets to 2030

Published - Jun 2026 | Publisher - BCC Publishing | Code - PHM035D

The global substance use disorder (SUD) treatment market was valued at $11.6 billion in 2025, and it is expected to reach $14.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2030.

In Vitro Toxicity Testing: Technologies and Global Markets

Published - May 2026 | Publisher - BCC Publishing | Code - PHM017H

The global in vitro toxicity testing market was valued at $17.4 billion in 2025 and is projected to reach $28 billion by the end of 2030, at a compound annual growth rate of 10% from 2025 to 2030.

Cardiovascular Drugs: Global Markets to 2030

Published - Apr 2026 | Publisher - BCC Publishing | Code - PHM191B

The global market for cardiovascular drugs was valued at $183.7 billion in 2025 and is estimated to reach $228.6 billion by 2030, at a compound annual growth rate (CAGR) of 4.5% from 2025 through 2030.

Emerging Drugs: Global Markets

Published - Apr 2026 | Publisher - BCC Publishing | Code - PHM291A

The report provides an overview of the global emerging drugs and analyzes market trends, segmented by molecule type, product type, therapeutic application, and end user. It includes global revenue for the base year of 2024 and estimated data for the forecast period 2025 through 2030. The report focuses on trends, challenges, and the competitive landscape, including market share of leading companies and company profiles with financials, product portfolios, and recent developments.

Top Trending Reports

2025 Medical Devices Research Review

Published - Apr 2026 | Publisher - BCC Publishing | Code - MDS060C

Get a concise view of the medical devices sector with BCC Research’s 2025 review covering market dynamics, emerging technologies and industry developments.

Cancer Profiling and Pathways: Technologies and Global Markets

Published - May 2026 | Publisher - BCC Publishing | Code - BIO073D

The global market for cancer profiling and pathway technologies is expected to grow from $18.3 billion in 2025 and is projected to reach $33.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.2% during the forecast period of 2025 to 2030.

Validation, Calibration, and Standardization in the Life Sciences Market

Published - Mar 2026 | Publisher - BCC Publishing | Code - BIO179B

The global market for validation, calibration, and standardization in life sciences was valued at $2.8 billion in 2025 and is estimated to reach $3.9 billion by 2030, at a compound annual growth rate (CAGR) of 6.7% from 2025 through 2030.

Glass Fiber: Global Markets

Published - May 2026 | Publisher - BCC Publishing | Code - AVM225B

The global market for glass fiber is expected to grow from $13.5 billion in 2026 and is projected to reach $17.2 billion by the end of 2031, at a compound annual growth rate (CAGR) of 4.9% during the forecast period of 2026 to 2031.

2025 Chemical Research Review

Published - Apr 2026 | Publisher - BCC Publishing | Code - CHM190B

BCC Research’s 2025 Chemical Research Review covering market trends, specialty chemicals, industrial innovation and growth opportunities across the chemical industry.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
Customize This Report
Customize Report
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.
Contact
© 2026 BCC Research
Privacy Policy |Site Map|Terms & Conditions
AI Sentiment